2005
Medical Services Advisory Committee (MSAC). 2005. High-energy transurethral microwave thermotherapy for benign prostatic hyperplasia. November 2005. Assessment report. Department of Health and Ageing, Commonwealth of Australia. Canberra.
Ray JA, Valentine WJ, Secnik K, Oglesby AK, Cordony A, Gordois A, Davey P, Palmer AJ. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Current Medical Research and Opinion. October 2005; 21(10):1617–1629.
Novello S, Kielhorn A, Stynes G, Selvaggi G, De Marinis F, Maestri A, Foggi P, Tilden D, Tonato M, Crinò L, Rinaldi M, Migliorino M, Scagliotti GV; Italian Lung Cancer Project Investigators. 2005. Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy. Lung Cancer 48: 379–87.
Aristides M, von der Maase H, Roberts T, Brown A, Kielhorn A, Bhalla S. 2005. Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer. European Journal of Cancer Care 14:141–2.
Price N, Davey P, Birinyi-Strachan L. 2005. The cost-effectiveness of olanzapine for the treatment of schizophrenia in Malaysia. Malaysian Journal of Psychiatry 13:53–62.
Davey P, Price N, Lees M, Makino K, Birinyi-Strachan L, Frost M. 2005. Comparison of reimbursement systems of various countries in central and eastern Europe, Africa, Middle East and Asia. ISPOR Connections 11(1):4–6.
Mudge MAC, Davey PJ, Coleman KA, Montgomery W, Croker VS, Mullen K, Castle DJ. 2005. A comparison of olanzapine versus risperidone for the treatment of schizophrenia—a meta-analysis of randomised clinical trials. International Journal of Psychiatry in Clinical Practice 9:3–15.
Blamey S, Barraclough B, Delbridge L, Mernagh P, Standfield L, Weston A. 2005. Using recombinant human thyroid-stimulating hormone for the diagnosis of recurrent thyroid cancer. ANZ Journal of Surgery 75:10–20.
Secnik K, Matza LS, Cottrell S, Edgell E, Tilden D, Mannix S. 2005. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United Kingdom. Medical Decision Making 25:56–70.
Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N, Manegold C, Pujol JL, van Zandwijk N, Gridelli C, van Meerbeeck JP, Crino L, Brown A, FitzGerald P, Aristides M, Schiller JH. 2005. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum-containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47: 69–80.
Stynes G, Gatzemeier U, Thatcher N, Bhalla S, Aristides M, Leschinger M, Tilden D. Do the published toxicity data from clinical trials in oncology give the full picture? An example using pemetrexed and docetaxel. 2005. In: Proceedings of the American Society of Clinical Oncology Annual Meeting. Journal of Clinical Oncology 23 (suppl 16S):8188.
Boundy K, Woodward M, Ames D, Aldridge G, Brodaty H, Byrne G, Snowdon J, Hertel J. Reduced extrapyramidal symptoms and tardive dyskinesia in patients with dementia receiving low-dose risperidone compared to low-dose haloperidol: a systematic review. 18th World Congress of Neurology, 5–11 November 2005, Sydney, Australia.
Ames D, Aldridge G, Brodaty H, Byrne G, Snowdon J, Woodward M, Hertel J. Reduced extrapyramidal symptoms and tardive dyskinesia in patients with dementia receiving low-dose risperidone compared to low-dose haloperidol: a systematic review. 12th Congress of the International Psychogeriatric Association, 20–24 September 2005, Stockholm, Sweden. Poster presentation.
Mersha Chetty, Anna Cordony, Peter Davey, Korina Karampela, James Symanowski, Corinne Le Reun, Mark Watt. Economic impact of adopting pemetrexed plus cisplatin for malignant pleural mesothelioma into Scottish clinical practice. ISPOR 8th Annual European Congress, 6–8 November 2005, Florence, Italy. Poster presentation.
Abela M, Palmer T, Measuring key performance indicators for developing a reimbursement strategy. 3rd Annual Pharma Marketing Congress, 18–19 May 2005, Sydney, Australia. Podium presentation.
Davey P, Cordony A, Rajan N, Arora B, Pavlakis N.Value-for-money of pemetrexed plus cisplatin versus cisplatin alone in the treatment of malignant pleural mesothelioma. ISPOR 10th Annual Meeting, 15–18 May 2005, Washington DC, USA. Podium presentation.
Abela M, Davey P, Carroll J, Brown B, Yates R. Developing key performance indicators for the Australian reimbursement system. ISPOR 10th Annual Meeting, 15–18 May 2005, Washington DC, USA. Poster presentation.
Adams J, LeReun C, Crowley S, Nand V, Eggleston A, Schrover R. Valuation of schizophrenia-related health states by the general population using the AQoL, time trade-off and visual analogue scales. ISPOR 10th Annual Meeting, 15–18 May 2005, Washington DC, USA. Poster presentation.
Makino K, Matsushita T, Davey P, Narita M, Mori S, Kimuro Y. A psychiatric hospital revenue and profitability model for the treatment of patients with schizophrenia in Japan. ISPOR 10th Annual Meeting, 15–18 May 2005, Washington DC, USA. Poster presentation.
Goodyer L, Cottrell S, Gandhi G, Aristides M. Preference and willingness-to-pay study to assess the value of anti-malarial chemoprophylactic medications using discrete choice analysis: a UK pilot study. 9th Conference of the International Society of Travel Medicine, 1–5 May 2005, Lisbon, Portugal. Poster presentation.
Ames D, Aldridge G, Brodaty H, Byrne G, Snowdon J, Woodward M, Hertel J. Reduced extrapyramidal symptoms and tardive dyskinesia in patients with dementia receiving low-dose risperidone compared to low-dose haloperidol: a systematic review. International Psychogeriatric Association Australasia Regional Meeting, 5–8 April 2005, Rotorua, New Zealand. Poster presentation.
Bae J, Arellano J, Aristides M, Cottrell S, Edgell E, Robinson P, Tilden D. A modelled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. 13th Congress of the Association of European Psychiatrists, 2–6 April 2005, Munich, Germany. Poster presentation.
2004
Warren E, Ward S, Gordois A, Scuffham P. 2004. Cost-utility analysis of imatinib mesylate for the treatment of chronic myeloid leukemia in the chronic phase. Clinical Therapeutics 26:1924–1933.
Weston A, Fitzgerald P. 2004. Discrete choice experiment to derive willingness-to-pay for methyl aminolevulinate photodynamic therapy versus simple excision surgery in the treatment of basal cell carcinoma. PharmacoEconomics. 22:1195–1208.
Aristides M, Weston A, Fitzgerald P, Le Reun C, Maniadakis N. 2004. Patient preference and willingness-to-pay for Humalog Mix25 relative to Humulin 30/70: a multi-country application of a discrete choice experiment. Value in Health 7:442–454.
Tilden DP, Chapman J, Davey PJ, Solly ML, Crowley S. 2004. A decision-analytic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation. Clinical Transplantation 18:312–320.
Robinson P, von der Maase H, Bhalla S, Kielhorn A, Aristides M, Brown A, Tilden D. 2004. Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer. Expert Review of Pharmacoeconomics and Outcomes Research 4:27–38.
Schiller J, Tilden D, Aristides M, Lees M, Kielhorn A, Maniadakis N, Bhalla S. 2004. Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer 43:101–112.
Price DB, Honeybourne D, Little P, Mayon-White RT, Read RC, Thomas M, Wale MC, Fitzgerald P, Weston AR, Winchester CC. 2004. Community-acquired pneumonia mortality: a potential link to antibiotic prescribing trends in general practice. Respiratory Medicine 98:17–24.
Secnik K, Cottrell S, Matza S, Edgell E, Aristides M, Tilden D, Burridge J, Mannix S. 2004. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent-based standard gamble scores. Value in Health 7:236 [abstract].
Medical Services Advisory Committee (MSAC). 2004. Faecal occult blood testing for population health screening. May 2004. Assessment report. Department of Health and Ageing, Commonwealth of Australia, Canberra.
Brown A, Aristides M, FitzGerald P, Liepa A, Boyer M, Clarke S. Pemetrexed versus docetaxel in the second-line treatment of advanced non-small-cell lung cancer. Evaluating patient preference. European Society for Medical Oncology, 29 October–2 November 2004, Vienna, Austria. Poster presentation.
De Marinis F, Crinò L, Stynes G, Aristides M, Guidi L, Liepa AM, Bhalla S. Improved toxicity profile of pemetrexed versus docetaxel in previously treated non-small-cell lung cancer patients translates to cost savings in Italy. European Society for Medical Oncology, 29 October–2 November 2004, Vienna, Austria. Poster presentation.
Adams J, Le Reun C, Crowley S, Nand V, Eggleston A. Schizophrenia and quality of life assessments. ISPOR 7th Annual European Congress, 24–26 October 2004, Hamburg, Germany. Podium presentation.
Launois R, Avoinet S, Le Lay K, Tilden D, Bhalla S, Kielhorn A, Chemali N. Gemzar retrospective economic analysis of clinical trials (GREAT2): a patient-level cost comparison of three chemotherapy regimens in the treatment of non-small-cell lung cancer in France. ISPOR 7th Annual European Congress, 24–26 October 2004, Hamburg, Germany. Poster presentation.
Bischoff H, Hamann M, Stynes G, Bhalla S, Tilden D, Kielhorn A. Comparative costs of gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of non-small-cell lung cancer in Germany. ISPOR 7th Annual European Congress, 24–26 October 2004, Hamburg, Germany. Poster presentation.
Watkins J, Kielhorn A, Bhalla S, Tilden D, Stynes G. Does gemcitabine plus cisplatin provide value for money in the treatment of advanced non-small-cell lung cancer in the UK? ISPOR 7th Annual European Congress, 24–26 October 2004, Hamburg, Germany. Poster presentation.
Kielhorn A, Stynes G, Bhalla S, Tilden D. A cost comparison of Gemzar plus cisplatin with other novel agents in the treatment of non-small-cell lung cancer in Italy. ISPOR 7th Annual European Congress, 24–26 October 2004, Hamburg, Germany. Poster presentation.
Kielhorn A, Dilla T, Stynes G, Tilden D, Bhalla S. Costs of treating advanced non-small-cell lung cancer in Spain using gemcitabine in combination with cisplatin: a comparison with other second-generation novel agents. ISPOR 7th Annual European Congress, 24–26 October 2004, Hamburg, Germany. Poster presentation.
Stynes G, Aristides M, Rosell R, Felip E, Liepa AM. Improved toxicity profile of pemetrexed vs docetaxel in previously treated non-small-cell lung cancer patients translates to cost savings in Spain. ISPOR 7th Annual European Congress, 24–26 October 2004, Hamburg, Germany. Poster presentation.
Brown AJ, Aristides M, Fitzgerald PE, Liepa AM, Boyer MJ, Clarke SA. Evaluation of pemetrexed versus docetaxel in the second-line treatment of advanced non-small-cell lung cancer: patient preference and willingness-to-pay with discrete choice conjoint analysis. ISPOR 7th Annual European Congress, 24–26 October 2004, Hamburg, Germany. Poster presentation.
Stynes G, Adams J, Tilden D, Garrett S, Wilson J. The burden of ankylosing spondylitis in Australia: an epidemiological and cost of illness model. ISPOR 7th Annual European Congress, 24–26 October 2004, Hamburg, Germany. Poster presentation.
Tilden D, Stynes G, Adams J, Garrett S. Quantifying disease severity as a determinant of costs and quality of life in patients with ankylosing spondylitis in Australia. ISPOR 7th Annual European Congress, 24–26 October 2004, Hamburg, Germany. Poster presentation.
Stynes G, Tilden D, Swift M, Cockle S, Haycox A, Aristides M. The cost-effectiveness of pioglitazone in combination with metformin in the treatment of type 2 diabetes mellitus in Scotland. ISPOR 7th Annual European Congress, 24–26 October 2004, Hamburg, Germany. Poster presentation.
Tilden D, Stynes G, Swift M, Cockle S, Haycox A, Aristides M. The value of oral monotherapy alternatives in the first-line treatment of type 2 diabetes mellitus. ISPOR 7th Annual European Congress, 24–26 October 2004, Hamburg, Germany. Poster presentation.
Wilson J, Burridge J, Gniel J, Maclean A, Le Reun C, Adams J, Davey P. Assessing the value of anastrozole as an alternative to tamoxifen for the treatment of early breast cancer (EBC) using discrete choice willingness-to-pay (WTP) methodology. ISPOR 7th Annual European Congress, 24–26 October 2004, Hamburg, Germany. Poster presentation.
Wilson J, Burridge J, Gniel J, Maclean A, Le Reun C, Adams J, Davey P. Assessing the value of anastrozole therapy relative to placebo for early breast cancer (EBC) using discrete choice willingness-to-pay (WTP) methodology, for women who cannot tolerate or are contraindicated for tamoxifen. ISPOR 7th Annual European Congress, 24–26 October 2004, Hamburg, Germany. Poster presentation.
FitzGerald P, Aristides M. Statistical issues in the analysis of discrete choice models. ISPOR 7th Annual European Congress, 24–26 October 2004, Hamburg, Germany. Poster presentation.
Schrover R, Christova L, LeReun C, Crowley S, Davey P, Birinyi-Strachan L. Indirect meta-analysis of rabeprazole versus esomeprazole via placebo in patients with healed erosive GORD. Australian Gastroenterology Week, 4–8 October 2004, Brisbane, Australia. Poster presentation.
Adams J, Le Reun C, Crowley S, Nand V, Eggleston A, Schrover R. The impact of schizophrenia on the quality of life of carers: a pilot study. Health Outcomes 2004: Perspectives on population health. 10th Annual National Health Outcomes Conference. 15–16 September 2004, Canberra, ACT. Podium presentation.
FitzGerald P, Tilden D. Multiple imputation for comparing QoL scores from different instruments. 22nd International Biometric Conference, 11–16 July 2004, Cairns, Australia. Podium presentation.
Stynes G, Aristides M, Manegold C, Mueller T, Lackoff A, Liepa AM. Improved toxicity profile of pemetrexed vs. docetaxel in previously treated non-small-cell lung cancer patients translates to cost savings in Germany. 16th International Multinational Association for Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO), 24–27 June 2004, Miami Beach, Florida, USA. Poster presentation.
Luxford K, Evans A, Zorbas H, Ewan C, Redman S, Rainbird K, Price N. 2004. Service delivery supporting quality cancer care: a national multidisciplinary care project for breast cancer. American Society of Clinical Oncology (ASCO) Annual Meeting, 5–8 June 2004, New Orleans, USA. Poster presentation.
Adams J. Conjoint analysis in the Australian pharmaceutical market place. Practical examples and the potential for future use. Australian Pharmaceutical Marketing and Research Group mid-seminar. 2 June 2004, Sydney, NSW. Podium presentation.
Dyer S, Standfield L, Tilden D, Mernagh P, Fitzgerald P. 2004. Assessment of the cost-effectiveness of M2A® capsule endoscopy to inform public funding policy in Australia. First Annual International Meeting of Health Technology Assessment International, 30 May– 2 June 2004, Krakow, Poland. Podium presentation.
Davey P, Lees M, Makino K, Price N, Birinyi-Strachan L. 2004. Comparison of reimbursement systems of various countries in central and eastern Europe, Africa and Middle East. ISPOR 9th Annual International Meeting, 16–19 May 2004, Arlington, VA, USA. Podium presentation.
Secnik K, Cottrell S, Matza S, Edgell E, Aristides M, Tilden D, Burridge J, Mannix S. 2004. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent-based standard gamble scores. ISPOR 9th Annual International Meeting, 16–19 May 2004, Arlington, VA, USA. Podium presentation.
Davey P, Price N, Lees M, Birinyi-Strachan L, Makino K, Mudge M. 2004. A retrospective comparison of the cost-effectiveness of olanzapine for the treatment of schizophrenia in selected non-OECD countries. ISPOR 9th Annual International Meeting, 16–19 May 2004, Arlington, VA, USA. Poster presentation.
Price N, Davey P, Mudge M, Fitzgerald B, Rajan N, Montgomery W. 2004. Cost-effectiveness of olanzapine versus lithium for the prevention of relapse in bipolar I disorder in Australia. ISPOR 9th Annual International Meeting, 16–19 May 2004, Arlington, VA, USA. Poster presentation.
Gordois A, Mudge M, Davey P, Aldridge G, Nobes M, Lees M, Toohey M. 2004. The cost-effectiveness of sirolimus with cyclosporin withdrawal versus low dose sirolimus and continued cyclosporin when initiated within four months of renal transplantation. ISPOR 9th Annual International Meeting, 16–19 May 2004, Arlington, VA, USA. Poster presentation.
Tilden D, Mernagh P, Fitzgerald P, Adams J, Schulz M, van Bavel J, Davey P. 2004. Patient preference and willingness-to-pay for Vioxx as a treatment for osteoarthritis relative to NSAIDs. ISPOR 9th Annual International Meeting, 16–19 May 2004, Arlington, VA, USA. Poster presentation.
Adams J, Le Reun C, Heavey M, Burke M, Flowers M, Germanos P, Lindsay P, Noble P, Webb K, Davey P. 2004. The impact of ACEI related cough: A survey of Australian patients. ISPOR 9th Annual International Meeting, 16–19 May 2004, Arlington, VA, USA. Poster presentation.